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Abstract
BACKGROUND: Many human tumors show aberrant activation of a group
of germline-specific genes, termed cancer-germline (CG) genes, several of
which appear to exert oncogenic functions. Although activation of CG genes
in tumors has been linked to promoter DNA demethylation, the mechanisms
underlying this epigenetic alteration remain unclear. Two main processes have
been proposed: awaking of a gametogenic program directing demethylation of
target DNA sequences via specific regulators, or general deficiency of DNA
methylation activities resulting from mis-targeting or down-regulation of the
DNMT1 methyltransferase. RESULTS: By the analysis of transcriptomic data, we
searched to identify gene expression changes associated with CG gene activation
in melanoma cells. We found no evidence linking CG gene activation with
differential expression of gametogenic regulators. Instead, CG gene activation
correlated with decreased expression of a set of mitosis/division-related genes
(ICCG genes). Int...
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Abstract
Background: Many human tumors show aberrant activation of a group of germline-specific genes, termed cancer-
germline (CG) genes, several of which appear to exert oncogenic functions. Although activation of CG genes in tumors
has been linked to promoter DNA demethylation, the mechanisms underlying this epigenetic alteration remain unclear.
Two main processes have been proposed: awaking of a gametogenic program directing demethylation of target DNA
sequences via specific regulators, or general deficiency of DNA methylation activities resulting from mis-targeting or
down-regulation of the DNMT1 methyltransferase.
Results: By the analysis of transcriptomic data, we searched to identify gene expression changes associated with CG
gene activation in melanoma cells. We found no evidence linking CG gene activation with differential expression of
gametogenic regulators. Instead, CG gene activation correlated with decreased expression of a set of mitosis/division-
related genes (ICCG genes). Interestingly, a similar gene expression signature was previously associated with depletion of
DNMT1. Consistently, analysis of a large set of melanoma tissues revealed that DNMT1 expression levels were often lower
in samples showing activation of multiple CG genes. Moreover, by using immortalized melanocytes and fibroblasts
carrying an inducible anti-DNMT1 small hairpin RNA (shRNA), we demonstrate that transient depletion of DNMT1 can
lead to long-term activation of CG genes and repression of ICCG genes at the same time. For one of the ICCG genes
(CDCA7L), we found that its down-regulation in melanoma cells was associated with deposition of repressive chromatin
marks, including H3K27me3.
Conclusions: Together, our observations point towards transient DNMT1 depletion as a causal factor of CG gene
activation in vivo in melanoma.
Background
Cancer development is a multistep process during
which neoplastic cells accumulate new properties that
progressively increase their malignant behavior [1]. This
stepwise progression is in part driven by the acquisition
of genetic mutations that modify the function of cancer-
related proteins [2]. Other driving forces are epigenetic
alterations, which affect both DNA and histone modifica-
tions and lead to reshaping of chromatin structures,
thereby permitting gene expression adaptations that favor
cancer progression [3].
One common epigenetic alteration in human tumors
concerns DNA methylation, a chemical modification
that affects cytosines in CpG sequences and is associated
with transcriptional repression [4]. Lineage-specific DNA
methylation patterns, which are established during embry-
onic development, are in general faithfully maintained in
differentiated adult cells. Enzymes involved in these pro-
cesses are the de novo methyltransferases DNMT3A and
DNMT3B, as well as the DNA methylation maintenance
methyltransferase DNMT1 [5]. In most tumor cells, gen-
ome methylation patterns become profoundly altered. Both
gains (hypermethylation) and losses (hypomethylation) of
DNA methylation are observed within the same tumor cell.
In many cases, hypermethylation affects the promoter of
tumor-suppressor genes and leads therefore to loss of
tumor-suppressive functions [3]. Compared with DNA
hypermethylation, DNA hypomethylation is more wide-
spread in cancer genomes, as it affects repeated sequences
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which are dispersed throughout all chromosomes [6]. DNA
hypomethylation was shown to promote tumor develop-
ment at least in part by increasing genome instability [7].
Another frequent target of DNA hypomethylation in
tumors comprises a particular group of germline-
specific genes, including about 50 genes or gene
families in human, which were grouped under the term
“cancer-germline” (CG) genes [8]. A common charac-
teristic of CG genes is that their repression in somatic
tissues primarily relies on DNA methylation, which
appears to act as a dominant component of transcrip-
tional regulation for these genes [9, 10]. As a result,
while CG genes are completely silenced in normal
somatic tissues, they become activated, often concomi-
tantly, in tumors with extensive genome hypomethyla-
tion. Aberrant activation of CG genes is observed in a
wide variety of tumors, including lung, head and neck,
œsophagal, bladder, and prostate carcinoma, as well as
melanoma [11]. CG genes were initially identified
because their activation in tumor cells generates the
expression of tumor-specific antigens, which can be recog-
nized by cytolytic T lymphocytes [12]. Therapeutical anti-
cancer vaccinations directed against such antigens are
currently being tested in the clinic. More recently, several
CG genes were also found to display oncogenic properties,
thereby suggesting that several of these genes may
contribute to tumor progression [13, 14].
The process leading to DNA demethylation and subse-
quent activation of CG genes in tumors is still unclear.
Two main possibilities have been envisaged. One involves
induction of a gametogenic program in cancer cells, which
would result from aberrant reactivation of critical master
regulators of germ cell development [11, 15]. In associ-
ation with TET methylcytosine oxidizing enzymes, such
regulators could elicit demethylation of target DNA
sequences [16–18]. The other possible cause of CG gene
hypomethylation in tumors relies on a general defect in
DNA methylation maintenance activities, and several
mechanisms that might cause such type of epigenetic im-
balance have been proposed. For instance, mis-localization
of DNMT1 in cancer cells, resulting from either impaired
recruitment to replication forks, disrupted interaction with
partner proteins, or translocation into a stress-induced
protein complex, has been reported [19–21]. Excessive pro-
liferation and deficiency in the production of the methyl
donor S-adenosylmethionine were also suggested as a pos-
sible cause of DNA demethylation in cancer [22]. Other
studies revealed down-regulation of DNMT1 expression in
tumor cells, via increased abundance of a regulatory
miRNA (miR29b) or over-expression of a partner protein
(UHRF1) that induces DNMT1 destabilization [23, 24]. It is
expected, however, that the process leading to DNA
demethylation operates during a transient period of tumor
development since established tumor cells (even those with
a hypomethylated genome) generally display normal DNA
methylation activities. Moreover, there is experimental
evidence to suggest that CG gene hypomethylation in can-
cers results from a historical event of transient DNA
demethylation [25].
By analyzing gene expression microarray data gener-
ated from a series of melanoma cell lines, we found that
CG gene activation is correlated with the presence of a
gene expression signature that has been previously asso-
ciated with DNMT1 depletion. This expression signature
was mainly characterized by the down-regulation of a
set of genes (ICCG genes) showing enrichment for
mitosis/division-related functions. In the present study,
we investigated the possibility that CG gene activation in
melanoma is the result of an episode of DNMT1 deple-
tion. To this end, we compared the level of DNMT1
expression in melanoma tissue samples displaying either
little or extensive activation of CG genes. Moreover, we
developed cellular models, which allowed to confirm that
transient depletion of DNMT1 can lead to coincident acti-
vation of CG genes and down-regulation of ICCG genes.
Finally, the mechanisms involved in permanent down-
regulation of ICCG genes were explored.
Results
A gene expression profile linking DNMT1 depletion with
CG gene activation in melanoma cell lines
In an effort to get better insight into the molecular path-
ways associated with the activation of CG genes in
tumors, we undertook transcriptomic analyses aiming at
identifying gene expression changes correlated with CG
gene activation. To this end, we exploited a publicly
available gene expression microarray dataset (GEO data-
base GSE4843, hereafter designated 45-MelCells), which
derives from a series of 45 human melanoma cell lines
[26]. We chose this dataset because it is known that
melanomas exhibit frequent activation of multiple CG
genes [12] and because cell lines offer the advantage of a
higher cellular homogeneity as compared to tumor tis-
sues. A CG gene activation score (CGAS) was calculated
for each of the 45 melanoma cell lines. This was per-
formed by evaluating the number of activated CG genes
among a set of 11 selected CG genes (Fig. 1a). CG genes
in this reference set were selected because their probe
intensity values were highly contrasted among the sam-
ples, thereby enabling clear distinction between their
active or repressed state. CGAS values among melanoma
cell lines did not show a normal distribution (D’Agostino
and Pearson omnibus normality test: p value =0.0012)
but rather indentified a group of 15 cell lines with no or
only few activated CG genes (CGAS ≤2) and another
group of 22 cell lines with a CGAS ≥7 (Fig. 1a). The 8
remaining cell lines displayed an intermediate CGAS, ran-
ging between 4 and 6. Further analysis of the 45-MelCells
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dataset revealed that a majority of other tested CG genes
also showed preferential activation in cell lines with a
CGAS ≥7 (Additional file 1: Figure S1). Together, these
observations confirmed previous data demonstrating that
melanomas tend to display either no CG gene activation
or coincident activation of multiple CG genes [27].
Microarray datasets were then further analyzed in
order to identify genes showing differential expression
levels between the two groups of melanoma cell lines
displaying a CGAS either ≤2 or ≥7. Using a maximum
10 % false discovery rate and a minimum 2.0 difference
of mean expression as criteria, only 14 genes were iden-
tified, which all showed increased expression in cell lines
with a CGAS ≥7 (Additional file 2: Table S1). Not sur-
prisingly, all these genes corresponded to previously
characterized CG genes. This approach therefore did not
allow us to identify genes, other than CG genes, display-
ing expression changes rigorously associated with CG
gene activation. In particular, we found no evidence of
association of CG gene activation with differential
expression of genes involved in germline development.
Analysis of the 45-MelCells microarray dataset with
less stringent statistical criteria (Mann–Whitney test,
p value <0.03 and difference in mean expression ≥1.5)
allowed identification of a larger set of genes that
were differentially expressed according to the CGAS.
Indeed, 192 genes, designated PCCG (positively corre-
lated with CG gene activation), and 64 genes, termed
ICCG (inversely correlated with CG gene activation),
displayed a trend towards increased or decreased expres-
sion levels in melanoma cell lines with a CGAS ≥7
(Fig. 1b, Additional file 2: Table S1). Functional an-
notation analyses indicated that PCCG genes were
enriched for the tumor antigen gene ontology term
(Fig. 1c). This was not surprising considering that
PCCG genes comprised many CG genes, in addition
to the CG genes that were used to define the CGAS.
Importantly, enrichment of CG genes among the
Fig. 1 A gene expression profile links DNMT1 depletion with CG gene activation in melanoma cell lines. a Establishment of a CG gene activation
score (CGAS) from the 45-MelCells dataset based on the expression profile of 11 selected CG genes (listed on the left). b Graphic representation
of genes showing differential expression levels between the groups of melanoma cell lines displaying a CGAS either ≤2 or ≥7. The genes were
classified from top to bottom according to their difference in mean expression. Two representative PCCG genes and four ICCG genes used in subsequent
analyses are highlighted. c Functional analysis of PCCG and ICCG genes (via DAVID Bioinformatics Resources 6.7). Each bar in the histogram represents the
Fisher exact p value (in a base 10 logarithmic scale) associated with the corresponding function in the group of genes. d Cross-comparison between the
set of DNMT1-regulated genes (n= 346, see ref. [28]) and either the PCCG or ICCG group of genes. Overlap scores are expressed as ratio between observed
and expected matches in a base 2 logarithmic (log2) scale. Statistical analysis was obtained by a Fisher test and compares in each group the number of
observed genes vs the number of expected genes. ****p< 0.0001
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PCCG group of genes supported the validity of the less
stringent statistical approach. ICCG genes on the other
hand, showed significant enrichment for mitosis/division-
related gene ontology terms (Fig. 1c).
The observation that CG gene activation in melanoma
cells is generally associated with down-regulation of genes
involved in cell mitosis and division was rather unex-
pected. It was however reminiscent of a previous study by
Sen and colleagues, who observed down-regulation of a
set of cell mitosis/division-associated genes in epidermal
cells that had been depleted of DNMT1 [28]. Interestingly,
we found that the Sen set of DNMT1-regulated genes
overlapped significantly with our group of ICCG genes
(Fig. 1d, Additional file 3: Figure S2). Analysis of another
study, where cells were exposed to a DNMT1 inhibitor
(GSE30985), revealed similar down-regulation of cell
mitosis/division-associated genes, as well as overlap of
these genes with the ICCG group of genes (Additional file
4: Figure S3). These initial observations raised therefore
the possibility that CG gene demethylation and activation
in melanoma cells might be the consequence of a process
of DNMT1 depletion.
CG gene activation is associated with DNMT1
down-regulation in melanoma tissues
If CG gene activation is associated with DNMT1 deple-
tion in melanoma, one would expect to find an inverse
correlation between the CGAS and the expression level
of DNMT1. This was not the case in the 45 melanoma
cell lines (Fig. 2a). However, when we analyzed an RNA-
seq dataset obtained from a collection of 278 cutaneous
melanoma tissue samples (TCGA), we observed that
DNMT1 expression levels were slightly, albeit signifi-
cantly, lower in samples displaying a higher CGAS
(Fig. 2b; p = 0.0413), even when adjusting for cell prolif-
eration rates (Additional file 5: Figure S4). Consistently,
melanoma tissue samples with a higher CGAS also
showed significant down-regulation of three out of out
representative ICCG genes (CDCA7L, CDCA7, ASF1B,
and CCNB1), which were selected from the original
ICCG group on the basis of highest anti-correlation
significance and variation coefficient in the 45-MelCells
analysis (Fig. 2a, b). Further evidence for an association
between DNMT1 down-regulation and CG gene activa-
tion in melanoma tissues was provided by the analysis of
immunohistochemistry-based protein expression data
(Human Protein Atlas), where we observed a trend
towards weaker staining for DNMT1 in melanoma tis-
sues scoring positive for CG proteins (Fig. 2c). Of note,
the mRNA expression of other genes involved in DNA
methylation (DNMT3A, DNMT3B, UHRF1, TET1, TET2,
and TET3) showed no correlation with the CGAS in
either melanoma cell lines or tissues (Fig. 2a, b). More-
over, analysis of clinical data from the TCGA collection
of melanoma revealed no significant correlation between
DNMT1 expression levels and Clark staging or patient
survival (Additional file 6: Figure S5).
Together our results indicate that CG gene activation
in melanoma tissues is associated with reduced expres-
sion of DNMT1. Lack of such a correlation in melanoma
cell lines may be related to the transient nature of the
DNMT1 depletion process. Thus, while this depletion
process is still in progress in several melanoma tissues,
DNMT1 expression levels are likely restored in most
melanoma cell lines that were expanded in vitro. CG
gene activation and ICCG gene down-regulation would
however persist past the transient phase of DNMT1
depletion. This scenario is in agreement with previous
studies suggesting that CG gene activation in tumors
results from a historical process of transient DNA de-
methylation [25, 29].
Establishing cell systems for experimental depletion of
DNMT1
The results described above suggested that CG gene
activation in melanoma results from a phase of DNMT1
depletion, which, at the same time, would induce down-
regulation of ICCG genes. To further examine this possi-
bility, we decided to verify if similar gene expression
changes can be recapitulated following experimental
depletion of DNMT1. To this end, we constructed a lenti-
viral vector harboring a doxycycline-inducible small hairpin
RNA (shRNA) directed against DNMT1 (pTshDNMT1).
The inducible transcript also comprised the sequence en-
coding the turbo Red Fluorescent protein (tRFP). A similar
vector containing an irrelevant shRNA sequence was used
as a control (pTctrl). The two vectors were transduced in
immortalized human melanocytes (HNEM-hTERT) and
fibroblasts (BJ-hTERT). Transduced clones carrying either
the pTshDNMT1 or the pTctrl vector were isolated from
these two cell types, and clones exhibiting near to 100 %
tRFP positive cells after doxycycline exposure were selected
(Additional file 7: Figure S6). RT-qPCR and immunoblot-
ting analyses confirmed marked reduction of DNMT1
expression, at both the mRNA and protein level, in the
pTshDNMT1 cell clones (but not in pTctrl clones) that had
been exposed to doxycycline (Fig. 3a, b).
AS DNMT1 depletion has been shown to cause pro-
liferation arrest in several cellular models [30, 31], we
evaluated the effect of doxycycline exposure on the
proliferation rate of both HNEM-hTERT and BJ-hTERT
derived clones. Cell counting experiments and cell cycle
analyses by flow cytometry indicated that whereas
DNMT1 depletion markedly reduced proliferation of
the HNEM-hTERT-derived pTshDNMT1 clone, it had
only little impact on the growth of the BJ-hTERT-
derived pTshDNMT1 clone (Fig. 3c, d).
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DNMT1 depletion leads to replication-dependent DNA
demethylation and activation of CG genes
We next examined the activation of CG genes in HNEM-
hTERT- and BJ-hTERT-derived pTshDNMT1 cell systems.
Six CG genes (MAGEA1, MAGEA3, CTCFL, CTAG2,
SSX1, and NXF2) were analyzed by RT-qPCR. The results
indicated that whereas all six CG genes were markedly
induced after 7 days of DNMT1 depletion in BJ-hTERT
Fig. 2 CG gene activation is associated with DNMT1 down-regulation in melanoma tissues. a The 45-MelCells dataset was analyzed for the
expression of seven DNA methylation-associated genes (DNMT1, DNMT3A, DNMT3B, UHRF1, TET1, TET2, and TET3) and of the four representative ICCG
genes. Graphs represent relative probe intensities for each gene (in a log2 scale), and each dot corresponds to one cell line. Cell lines were separated
into two groups according to their CGAS (≤2 and ≥7). Differential gene expression between the two groups were evaluated (Mann–Whitney tests),
and genes showing a significant p value are shown in bold (*p < 0.05, **p < 0.01). Red bars represent the median. b A similar analysis was performed in
a dataset of melanoma tissue samples (TCGA). Samples were grouped according to their CGAS: CGAS-low and CGAS-high correspond to the lower
and upper quartile, respectively (n = 70 in each group). P values were obtained as described here above. *p < 0.05, **p < 0.01, ***p < 0.001. c Analysis of
immunohistochemistry (IHC)-based protein expression data in melanoma tissues (Human Protein Atlas). Melanoma samples where IHC data were available
for both DNMT1 and CG protein levels are presented
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cells, their expression remained unchanged in similarly
treated HNEM-hTERT cells (Fig. 4a). Consistently, analysis
of the methylation status of the promoter of one of the CG
genes (MAGEA1) by methylation-specific PCR revealed no
apparent demethylation in the HNEM-hTERT-derived
pTshDNMT1 cells that had been exposed for up to
14 days to doxycycline (Fig. 4b). In BJ-hTERT-derived
pTshDNMT1 cells instead, DNMT1 depletion was ac-
companied by marked demethylation of the MAGEA1
promoter (Fig. 4b). We also examined genome-wide
DNA methylation changes, by using a methylation-
specific PCR directed towards long interspersed ele-
ments (LINE-1), which are found in large numbers
across the human genome. The results indicated that
whereas DNMT1 depletion-induced significant genome
demethylation in BJ-hTERT cells, only little DNA
methylation changes were observed in similarly treated
HNEM-hTERT cells (Fig. 4b).
Together, our results validated the HNEM-hTERT and
BJ-hTERT-derived clones as valuable systems to induce a
phase of DNMT1 depletion. Consequent DNA demethyla-
tion and activation of CG genes was however observed
only in BJ-hTERT-derived cells. Lack of a similar response
in HNEM-hTERT cells is likely due to their proliferation
arrest following depletion of DNMT1. Loss of DNA
methylation upon DNMT1 depletion requires indeed
several cycles of cell divisions.
DNMT1 depletion induces down-regulation of ICCG genes
We then used the validated HNEM-hTERT- and BJ-
hTERT-derived clones to investigate the effect of a phase
of DNMT1 depletion on the expression of ICCG genes.
To this end, pTshDNMT1 and pTctrl cell clones were
maintained in doxycycline-containing or control medium
during 7 days, and the mRNA level of the four reference
ICCG genes (CDCA7L, CDCA7, ASF1B, and CCNB1) was
analyzed by RT-qPCR. The results revealed significant
decrease of all four ICCG mRNAs in doxycycline-treated
Fig. 3 Validation of melanocyte and fibroblast cell systems for
experimental depletion of DNMT1. a The DNMT1 mRNA expression
levels were measured by quantitative RT-PCR in HNEM-hTERT- and
BJ-hTERT-derived pTctrl and pTshDNMT1 clones. The clones were
exposed (+ doxy) or not (− doxy) to doxycycline (1 μg/mL—7 days).
Expression values represent the mean (± sem) of at least three
independent experiments. ****p< 0.0001. b Protein levels of DNMT1 and
pKu80 (a loading control) were evaluated by Western-blot in the different
clones, either with or without exposure to doxycycline. c The number of
population doublings of HNEM-hTERT- and BJ-hTERT-derived clones, with
or without 7 and 14 days doxycycline exposure, were determined by cell
counting. Results derive from two independent experiments. d FACS
analysis was performed on HNEM-hTERT- and BJ-hTERT-derived
pT-shDNMT1 clones exposed or not to doxycycline (7 days). Propidium
iodide staining (X axis) was measured and the percentage of cells in
each cell cycle phase was determined
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pTshDNMT1 clones deriving from both HNEM-hTERT
and BJ-hTERT cells (Fig. 5).
Considering that all four reference ICCG genes dis-
play cell cycle-associated expression (Additional file 8:
Figure S7), it was possible that decreased mRNA amounts
in DNMT1-depleted cells reflected a reduced proportion
of proliferating cells rather than a process of gene repres-
sion. This was however unlikely to be the case for BJ-
hTERT cells, which showed no obvious proliferation
change upon DNMT1 depletion. To further confirm this,
we tested the effect of DNMT1 depletion on the mRNA
level of three genes (KIF5B, PWP1, and CEP70) that were
not included in the ICCG group of genes but nevertheless
display proliferation-associated expression, as evidenced
by available cell cycle-associated mRNA expression
data (http://www.cyclebase.org) and RT-qPCR experi-
ments in serum-deprived BJ-hTERT cells (Additional file 8:
Figure S7). The results showed that unlike ICCG genes, the
three non-ICCG (yet proliferation-associated) genes dis-
played no significant mRNA decrease upon depletion of
DNMT1 in BJ-hTERT cells (Fig. 5). In HNEM-hTERT cells,
DNMT1 depletion was associated with reduced expression
of PWP1 and CEP70, probably as a consequence of the
concurrent proliferation arrest in this cell type (Fig. 5).
Together, these observations confirm the association
between depletion of DNMT1 and reduced expression of
ICCG genes. Moreover, results in BJ-hTERT cells indicate
that this association is not merely a consequence of
reduced cell proliferation but likely involves a process of
selective gene repression.
Activation of CG genes and down-regulation of ICCG
genes persist past a transient phase of DNMT1 depletion
As mentioned above, the phase of DNMT1 depletion at
the origin of CG gene activation in tumors likely occurs
transiently during tumor development. It was therefore
essential to test if CG gene activation and ICCG gene
down-regulation would persist past a temporary period
of experimental depletion of DNMT1. We resorted
exclusively to the BJ-hTERT-derived cell system for this
analysis because HNEM-hTERT cells were found to cease
proliferation upon DNMT1 depletion. Thus, BJ-hTERT-
pTshDNMT1 cells were cultured in control or doxycycline-
containing medium for 7 days. After this period, cells were
transferred to normal medium and post-treatment clones
were derived by limiting dilution (Fig. 6a). RT-qPCR experi-
ments in treated cell populations confirmed that whereas
the DNMT1 expression level was strongly reduced at the
end of doxycycline exposure, it was almost completely
restored 7 days after withdrawal of the drug (Fig. 6b).
Clones deriving from either the control (18 clones) or
doxycycline-treated (24 clones) BJ-hTERT-pTshDNMT1,
cell populations were expanded in normal medium, and
after up to 12 weeks, they were harvested for RT-qPCR
Fig. 4 DNMT1 depletion leads to replication-dependent DNA demethylation and activation of CG genes. a The mRNA expression levels of DNMT1 and of
three CG genes (MAGEA1, MAGEA3, and CTCFL) were analyzed in HNEM-hTERT- and BJ-hTERT-derived clones exposed or not to doxycycline during 7 days.
Values, which derive from al least three independent experiments, were normalized by the ACTINB expression level and are expressed relative to the levels
found in − doxy cells. b DNA methylation levels within the MAGEA1 5'-region and LINE-1 sequences were evaluated by MS-qPCR in the different clones,
either with or without exposure (7 or 14 days) to doxycycline. Data represent the mean (± sem) of four independent qMS-PCR experiments, each in
duplicate. *p < 0.05, ***p < 0.001, ****p < 0.0001
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analyses. In each of these clones, we evaluated the
expression levels of a CG gene (MAGEA1), the four
reference ICCG genes (CDCA7L, CDCA7, ASF1B, and
CCNB1), and the three control non-ICCG genes
(KIF5B, PWP1, and CEP70). RT-qPCR results for
MAGEA1 revealed persistent activation of this CG
gene in 5 out of the 24 post-doxycycline clones and
in none of the control clones (Fig. 6c). This suggested
that only a proportion of post-doxycycline clones
reached a sufficient threshold of DNMT1 depletion to
permit CG gene demethylation and activation. RT-qPCR
results for the ICCG genes revealed that 3 out of these
genes (CDCA7L, CDCA7, and ASF1B) had expression
levels that were significantly lower in post-doxycycline
clones, as compared with control clones (Fig. 6c). None of
the non-ICCG genes showed this trend (Fig. 6c). Interest-
ingly, clones that showed MAGEA1 activation displayed
significantly lower levels of expression of all four ICCG
genes, as compared with the other 19 post-doxycycline
clones (Fig. 6c).
Together, these results confirm that depletion of
DNMT1 can lead to coincident CG gene activation and
ICCG gene down-regulation and indicate that these two
opposite gene expression changes persist past the transi-
ent phase of DNMT1 depletion.
RB1 is involved in ICCG gene regulation
While we searched to identify factors possibly involved
in transcriptional down-regulation of ICCG genes, we
noticed that all four reference ICCG genes (CDCA7L,
CDCA7, ASF1B, CCNB1) were previously reported to
contain functional E2F binding elements within their
promoter [32, 33]. This suggested that the E2F/RB1
pathway might be involved in the transcriptional regula-
tion of these genes. To confirm this, we examined the
level of mRNA expression of the four reference ICCG
genes following restoration of RB1 expression in RB1-
defective SAOS-2 cells. The results revealed significant
down-regulation of all four ICCG genes in SAOS-2 cells
that had been transfected with a RB1-encoding vector
(Fig. 7a), suggesting that RB1 acts as a transcriptional
repressor for these genes. In order to extend this finding
to the other ICCG genes, we compared the list of 64
ICCG genes with a list of 165 previously identified RB1-
regulated genes [34]. We observed significant overlap
between these two lists of genes (Fig. 7b), thereby
confirming enrichment of RB1-regulated genes within
the group of ICCG genes. Moreover, analysis of gene
expression data obtained from cells exposed to shRNA
inhibitors directed against RB1 or against each of the
two other RB-family proteins p107 and p130 suggested
Fig. 5 DNMT1 depletion induces down-regulation of ICCG genes. The mRNA expression levels of the four representative ICCG genes and of three
non-ICCG genes (KIF5B, PWP1, and CEP70) were determined by RT-qPCR in HNEM-hTERT- and BJ-hTERT-derived clones with or without exposure
to doxycycline (7 days). Values, which derived from at least four independent experiments, were normalized by the ACTINB expression level and
are expressed relative to the levels found in − doxy cells
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exclusive involvement of RB1 in the regulation of ICCG
genes (Additional file 9: Figure S8). Interestingly,
immunoblotting experiments revealed that DNMT1
depletion was associated with an increased amount of
RB1 protein in BJ-hTERT cells (Fig. 7c). Together, these
observations suggest that RB1 might contribute to the
process of ICCG gene down-regulation that occurs dur-
ing the phase of DNMT1 depletion.
Epigenetic mechanisms associated with CDCA7L
repression in melanoma cells
We next searched to get more insight into the molecular
mechanisms that contribute to persistent down-regulation
of ICCG genes in melanoma cells. To address this issue,
we focused our studies on CDCA7L because repression of
this ICCG gene was most significantly correlated with CG
gene activation in melanoma tissues (Fig. 2b). Compared
to other ICCG genes, CDCA7L also showed the most
extensive level of repression in melanoma cell lines
(Fig. 2a). This was confirmed by RT-qPCR experiments
showing that whereas CDCA7L is expressed in melano-
cytes, it is almost completely silenced in several melanoma
cell lines (Fig. 8a).
One possible explanation for the persistent repression
of CDCA7L in melanoma cells was that DNMT1 deple-
tion led to the irreversible activation of a factor that
Fig. 6 Activation of CG genes and down-regulation of ICCG genes persist past a transient phase of DNMT1 depletion. a Schematic outline of the
experiment. BJ-hTERT-pTshDNMT1 cells were cultured in the absence (ctrl) or in the presence of doxycycline (doxy) for 7 days (d7), and thereafter,
in normal medium during seven more days (d7 + 7). Control and post-doxy cell populations were then cloned by limiting dilution. RNA was extracted
from clones between day 36 and 82. b DNMT1 expression levels were analyzed by RT-qPCR in control and treated cell populations at the indicated
time points. Data, which derived from at least four independent experiments, were normalized with ACTINB expression level and are expressed relative
to the levels found in control cells. **p < 0.01. c Expression levels of the CG gene MAGEA1, the four ICCG genes, and the three non-ICCG genes were
assessed by RT-qPCR in control and post-doxy clones. Red dots correspond to clones showing activation of MAGEA1. Black bars correspond to the
mean. **p < 0.01, ***p < 0.001, ****p < 0.0001
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imposes silencing of the gene. To study this possibility,
we decided to evaluate the activity of the CDCA7L pro-
moter in melanoma cell lines that either do or do not
express the gene. We reasoned that if CDCA7L repression
is linked to the presence of a silencing factor, the promoter
of the gene would show reduced activity in non-expressing
melanoma cell lines. Thus, we constructed a plasmid vector
in which the CDCA7L promoter was inserted upstream of
the d2EGFP encoding sequence. The plasmid also contains
a neomycin-resistance gene (NEO) under the control of the
ubiquitously active SV40 promoter (Fig. 8b). This construct
was stably transfected into two melanoma cell lines that
express CDCA7L (Mi665/2 and SK-MEL-23) and two
melanoma cell lines that show silencing of the gene
(MZ2-MEL3.1 and BB74-MEL). Transfected cell popu-
lations were selected on the basis of neomycin resist-
ance, and the CDCA7L promoter activity was evaluated
by calculating the ratio between d2EGFP and NEO
mRNA levels. The results revealed that the activity of
the CDCA7L promoter was not significantly reduced in
CDCA7L-negative cell lines, as compared with CDCA7L-
positive cell lines (Fig. 8b). These observations argued
against the involvement of a transcriptional repressor in
the persistent repression of CDCA7L in melanoma cells.
Another possible explanation for the permanent
repression of CDCA7L in melanoma cells was that down-
regulation of this gene during the phase of DNMT1 deple-
tion allowed local deposition of repressive epigenetic
marks, which progressively locked the gene into an
irreversible silent state. Such type of opportunistic process
of epigenetic conversion has been previously described
[25, 35]. We first examined if CDCA7L repression in mel-
anoma cell lines was associated with DNA hypermethyla-
tion within its promoter. Bisulfite-sequencing experiments
revealed that CDCA7L repression was associated with
significant promoter hypermethylation in one cell line
(MZ2-MEL3.1; Fig. 8c). However, two other CDCA7L-
negative cell lines (LB1610-MEL and BB74-MEL) showed
only little DNA methylation within the gene promoter
(Fig. 8c), indicating that CDCA7L repression is not solely
due to promoter hypermethylation. We therefore per-
formed chromatin immunoprecipitation experiments to
investigate if repression of the CDCA7L gene is associated
with changes in histone modifications within its promoter
region. The results indicated that CDCA7L repression was
consistently associated with losses of the activating histone
mark H3K4me2 and with gains in the repressive histone
mark H3K27me3 (Fig. 8d). Altogether, these results support
the hypothesis that permanent repression of CDCA7L in
melanoma cells is linked to progressive deposition of
repressive epigenetic marks within the gene promoter.
Discussion
Because of the very restricted pattern of expression of
CG genes and their frequent activation in a wide variety
of tumors, antigens encoded by these genes are currently
being tested in clinical trials of anti-cancer vaccination.
Moreover, growing evidence indicates that several CG
genes display oncogenic properties [13, 14], and it is
expected that oncogenes with such a restricted pattern
of expression will represent ideal targets for the develop-
ment of anti-cancer therapies with limited side effects
[36]. Understanding the epigenetic mechanisms that lead
to CG gene activation in tumors constitutes an essential
issue in these perspectives.
An intrinsic property of epigenetic modifications is
that they remain in place even after the signal that initi-
ated their establishment has dissipated. The molecular
process at the origin of an epigenetic alteration can
therefore be difficult to identify, as it may be no longer
operating at the time of analysis. This probably explains
Fig. 7 RB1 is involved in ICCG gene regulation. a mRNA expression
levels of the four ICCG genes were evaluated by RT-qPCR in SAOS-2 cells
transfected with a vector coding for the RB1 protein (pRB) or with a
vector coding for a truncated and non-functional protein (pRBΔ). Data
were normalized with ACTINB expression levels and are expressed relative
to the levels found in the pRBΔ cells. Values represent the mean (± sem)
of at least three independent experiments. *p< 0.05, ***p< 0.001. b
Analysis for the presence of 165 previously characterized RB1-regulated
genes [34] among PCCG and ICCG genes. Histograms represent the ratio
between observed and expected matches, in a base 2 logarithmic scale.
Statistical analysis was obtained by a Fisher test comparing observed vs.
expected matches. *p< 0.05. c Western-blot was performed to analyze
RB1 protein expression in BJ-hTERT-derived clones, either with or
without 7 days exposure to doxycycline. pKu80 protein was used
as a loading control
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why the mechanisms underlying CG gene demethylation
and activation in tumors have remained unexplained. Our
data indicate that, at least in melanoma, activation of CG
genes is due to a phase of DNMT1 depletion. A first line of
evidence was provided by our observation that activation of
CG genes in melanoma cells correlates with the presence
of a gene expression signature that has been previously as-
sociated with DNMT1 depletion [28]. This signature is
characterized by the down-regulated expression of a set of
mitosis/division-related genes (ICCG genes) and can there-
fore be related to the mitotic disturbances that were re-
ported to occur upon DNMT1 depletion [30]. Our cellular
models provided experimental confirmation of the impact
of DNMT1 knockdown on ICCG gene expression. They
also demonstrated that down-regulation of these genes
persists past the phase of DNMT1 depletion. This explains
why the gene expression signature could still be detected in
melanoma cell lines, which otherwise showed restored
DNMT1 expression levels. A second line of evidence impli-
cating transient DNMT1 depletion as a causal factor of CG
gene activation in melanoma was provided by careful exam-
ination of expression data deriving from a large set of
melanoma tissues. This analysis revealed lower DNMT1
expression levels in melanoma samples showing activation
of multiple CG genes. This suggests that part of the analyzed
melanoma tissue samples were still undergoing the process
of DNMT1 depletion at the time they were removed, and
many of these samples also expressed CG genes. Together,
our findings are consistent with previous in vitro studies
demonstrating that experimental knockdown of DNMT1
constitutes a sufficient trigger to induce activation of mul-
tiple CG genes [37, 38]. Importantly, we now provide
evidence that a process of DNMT1 depletion actually occurs
in vivo in melanoma and is linked with CG gene activation.
Fig. 8 Epigenetic mechanisms associated with CDCA7L repression in melanoma cells. a CDCA7L mRNA expression levels were assessed in immortalized
normal melanocytes (HNEM-hTERT) and in five melanoma cell lines (Mi665/2 and SK-MEL-23, MZ2-MEL3.1, LB1610-MEL, and BB74-MEL). Values represent
mean (± sem) of at least two independent RT-qPCR experiments, each in duplicate. b Schematic representation of the pCDCA7L-prom/d2EGFP plasmid
(left panel). Four melanoma cell lines were stably transfected with the pCDCA7L-prom/d2EGFP plasmid, and d2EGFP mRNA expression levels were evaluated
(right panel). Results were normalized with NEO gene expression levels. Data represent mean (± sem) of three independent RT-qPCR analyses, each in
duplicate. c Bisulfite sequencing analyses of the CDCA7L 5'-region were performed in HNEM-hTERT cells and in four melanoma cell lines displaying
CDCA7L expression or repression (CDCA7L+ or −, respectively). Methylated and unmethylated CpGs are represented by filled and empty
boxes, respectively. Overall CpG methylation percentages (%) are indicated. d Quantitative ChIP analyses were applied to four melanoma
cell lines displaying either CDCA7L expression (SK-MEL-23, Mi665/2) or repression (MZ2-MEL3.1, BB74-MEL). Enrichment of indicated histone
modifications were evaluated within the CDCA7L 5′-region (GAPDH served as a control, ubiquitously active, promoter). Data derive from at
least two independent ChIP experiments, with two duplicate qPCR measures in each case
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Whereas we uncovered an epigenetically fixed gene
expression signature in melanoma cells attesting their
transition through an episode of DNMT1 depletion, no
similar gene expression signature was observed in other
tumor types. This suggests that DNA hypomethylation
and CG gene activation rely on alternative mechanisms
in other cancers, as evidenced by recent studies in brain
and colon cancer [20, 21]. It remains possible, however,
that tumors other than melanoma experience a phase of
transient DNMT1 depletion, which in this case would
not be associated with permanent acquisition of the gene
expression signature we identified.
The down-regulated expression of mitosis/division-
related genes during DNMT1 depletion likely reflects a
cellular stress response. A stress response has been
previously reported upon DNMT1 knockdown and was
shown to evolve into mitotic catastrophe in the case of
complete abolition of DNMT1 expression, for instance,
following conditional deletion of the gene [30, 31]. The
DNA damage sensing protein ATR appears to be involved
in the DNMT1-depletion stress response [39], and our ob-
servations suggest contribution of the connected RB1
pathway. An intriguing observation is that down-
regulation of mitosis/division-related genes is maintained
past the phase of DNMT1 depletion. The physiological
relevance of this phenomenon is unclear. With the excep-
tion of CDCA7L, affected mitosis/division-related genes
displayed, however, only partial repression in melanoma
cells. It is therefore likely that these genes retain a suffi-
cient level of expression to support ongoing cell
proliferation. On the long run, however, diminished ex-
pression of such genes may increase the rate of mitotic er-
rors in tumor cells, and thereby, favor genomic instability.
The way the stress response induced by DNMT1
depletion impacts on cellular proliferation appears to
vary according to the cell type. In our cellular models,
we observed that DNMT1 depletion-induced cell cycle
arrest in HNEM-hTERT melanocytes (essentially in G1)
but not in BJ-hTERT fibroblasts. Our observation that
the two cell types differed in the level of DNMT1 deple-
tion that was reached upon induction of the anti-DNMT1
shRNA (66 % mRNA reduction in fibroblasts vs. 87 % in
melanocytes) provides one possible explanation for these
contrasting outcomes. Another explanation may relate to
intrinsic differences between HNEM-hTERT melanocytes
and BJ-hTERT fibroblasts in the molecular pathways that
act downstream of the DNMT1 depletion-induced stress
response. Importantly, whether cells do or do not arrest
proliferation upon DNMT1 depletion determines the
extent of subsequent DNA demethylation. Passive DNA
demethylation resulting from lack of DNMT1 maintenance
activity requires indeed several replication cycles. Consist-
ently, we observed that DNMT1 depletion induced DNA
hypomethylation and CG gene activation in unarrested
fibroblasts but not in arrested melanocytes. A similar diver-
gence in proliferative response to DNMT1 depletion may
account for the observation that DNA methylation inhibi-
tors induce CG gene activation more efficiently in tumor
cells than in normal cells [40]. Clearly, understanding the
molecular mechanisms that underlie such divergent prolif-
erative reactions could help to predict cell type-specific pro-
pensities to undergo DNA demethylation upon DNMT1
inhibition. This may be critical when considering the use of
DNMT1 inhibitors in anti-cancer therapies.
A major perspective will be to uncover the mechanisms
that are responsible for the phase of DNMT1 depletion in
melanoma cells. Several studies have reported DNA
demethylation and reduced DNMT1 activities in cells
approaching senescence [41–44]. Cellular senescence,
which was shown to constitute an early (but escapable)
barrier to melanoma development [45], represents there-
fore a possible origin to the phase of DNMT1 depletion.
Tumor hypoxia represents another possible cause of
DNMT1 depletion. DNA demethylation and decreased
DNMT1 expression were indeed observed in cells that
were cultured under hypoxic conditions [46–48]. As for
many other tumor types, hypoxia represents an important
step in melanoma progression [49].
Conclusions
In summary, our present study provides in vivo evidence
that aberrant activation of CG genes in melanoma is the
result of a past event of DNMT1 depletion. This finding
reveals therefore that activation of this group of germline-
specific genes in tumor cells is due to a process of global
disruption of DNA methylation activities rather than to
awaking of a specific gametogenic program, as was previ-
ously proposed [11, 15]. An unexpected observation was
that DNMT1 depletion leads not only to gene activation
but also to irreversible down-regulation of a defined set of
mitosis/division-related genes. This epigenetically fixed
gene expression signature enabled us to track down the
origin of CG gene activation in melanoma. An important
observation of our study is therefore that gene expression
signatures can be used to trace back the epigenetic history
of tumors. This may proof valuable for tumor classifica-
tion and, hence, therapeutic decision-making.
Methods
Analysis of melanoma cell lines and tissues datasets
For melanoma cell lines, we used the dataset GSE4843
(Mannheim dataset) from the GEO database, which was
obtained on Affymetrix Human Genome U133 Plus 2.0
Array [26]. The raw signal intensity data had been previ-
ously scaled to an arbitrary mean value of 500 by MAS 5.0
software (Affymetrix). Genes with a score value inferior to
20 in all 45 cell lines were excluded from the analysis. The
expression values of 11 CG genes (see Fig. 1a) in each
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sample was reported to the mean value in all samples. We
used these relative expression levels to calculate the CG
gene activation score (CGAS) for each cell line. The mini-
mum threshold for CG gene activation was defined so as
to match the proportion of CG gene negative/positive
(~50 %) samples observed in human melanoma tumors
[50]. To identify genes showing differential expression
levels between melanoma cell lines with a CGAS either ≤2
or ≥7, we performed a nonparametric Mann–Whitney test
and calculated the independent False Discovery Rate
(FDR) for each gene in the dataset. In a first time, we used
a maximum 10 % FDR and a minimum 2.0 difference of
mean expression as selection criteria. Then, we resorted
to a less stringent analysis by using the Mann–Whitney
p value <0.03 and difference of mean expression ≥1.5 as
selection thresholds. Functional analysis was performed
using DAVID Bioinformatics Resource 6.7. For melanoma
tissues, we resorted to RNA-seq datasets from the Skin Cu-
taneous Melanoma dataset (TCGA, provisional; n = 278),
which accessed via the cBioPortal database [51, 52]. The
CGAS was calculated as described above, and tissues were
then separated into two groups: the “low CGAS” group,
which corresponds to the lower quartile and is composed
of 70 melanoma tissues expressing little CG genes, and the
“high CGAS” group, which corresponds to the upper
quartile and is composed of 70 melanoma tissues
expressing multiple CG genes.
Cell lines
All human melanoma cell lines, which derive from cutane-
ous melanoma metastases, were obtained from the Brussels
Branch of the Ludwig Institute for Cancer Research and
were cultured as previously described [9]. Immortalized hu-
man fibroblasts BJ-hTERT cells were kindly provided by F.
d’Adda di Fagagna (IFOM foundation, Italy), and their cul-
ture conditions are described elsewhere [14]. Immortalized
human melanocytes HNEM-hTERT cells were received
from E. De Plaen (Ludwig Institute for Cancer Research,
Belgium) and were cultured in MBM-4 medium supple-
mented with growth factors (#CC-3249, Lonza) and
endothelin-3 (#CC-4510, Lonza). SAOS-2 osteosarcoma
cell lines, which were a gift from F. Journe (ULB, Belgium),
were cultured as previously described [53]. Cell cultures
were maintained at 37 °C in a humidified atmosphere of
8 % CO2 for all melanoma cell lines and at 5 % CO2 for the
other cell lines.
Transductions and doxycycline treatment
The pTRIPZ-shDNMT1 (pTshDNMT1) vector was con-
structed by inserting a shRNA sequence directed against
DNMT1 into the pTRIPZ-empty (pTctrl) vector (Thermo
Scientific). The shRNA sequence was amplified from cells
that were transduced with lentiviral particles coming from
ThermoScientific Open Biosystems (#V3LHS_358136). To
insert the shRNA sequence into the pTRIPZ vector, we
resorted to primers 5′-CAGGTTAACCCAACAGAAGG
CT-3′ and 5′-GTAATCCAGAGGTTGATTGTTCCA-3′,
which carry a 5′-overhang containing a XhoI or a MluI re-
striction site, respectively. BJ-hTERT and HNEM-hTERT
cells were then incubated with lentiviral supernatant
containing either pTctrl or pTshDNMT1 plasmids and
8 μg/mL polybrene for 5 h. Three days later, cells were se-
lected with 2.5 and 3 μg/mL puromycin (InvivoGen) for
BJ-hTERT and HNEM-hTERT, respectively. Puromycin-
resistant cells were finally cloned by limiting dilutions. To
induce the shRNA expression from the pTshDNMT1 vec-
tor, stably transduced cells were submitted to the addition
of 1 μg/mL of doxycycline (Clontech) into the culture
medium for 7 or 14 days with renewal every second day.
Plasmid constructions and transfections
The vector coding for the RB protein (plasmid 413 pSG5L
HA RB from Addgene) was used to construct a control
vector (pRBΔ). We used the EcoRI enzyme to digest the
pRB vector into two fragments (of ~4.9 and 1.9 kb), and we
kept the longer fragment to circularization. This control
vector contains only the first tier of the total RB sequence
and encodes a truncated and non-functional protein. The
pRB or pRBΔ vector was transfected into SAOS-2 cells by
using calcium phosphate coprecipitation. The culture
medium was replaced 24 h after transfection by serum-free
medium for an additional 24 h before RNA extraction.
To construct the pCDCA7L-prom/d2EGFP vector, we
amplified a 2270 bp fragment of the CDCA7L promoter
from human MZ2-MEL3.1 cells, using PrimeSTAR HS
DNA Polymerase (Takara). Due to the presence of multiple
HindIII restriction sites into the CDCA7L-promoter, a three
sequential steps construction was performed. The first step
was done to amplify the first part of the CDCA7L promoter
(419 bp) by using primers 5′-CCGAAGCTTAGTATT
ACTGCAGTGCCATGT-3′ and 5′-AATTCAATCAGAG
CTCTTCTTCCTCTTTT-3′, which carry a 5′-overhang
HindIII and a SacI restriction site, respectively. This
sequence was introduced into the pMAGEA1/hph vector
[38], after digestion by HindIII and SacI, which at the same
time allowed eviction of the MAGEA1 sequence from the
vector. Then, a second step was used to amplify the second
part of the CDCA7L promoter (1851 bp) with the
primers 5′-AAAAGAGGAAGAAGAGCTCTTGATTG
AATT-3′ and 5′-GCCGTCGACTCTTCCTAACCGGG
CTCCA-3′, which contain a SacI and a 5′-overhang
SalI restriction site, respectively. This sequence was
also introduced into the pMAGEA1/hph vector after
digestion by SacI and SalI, immediately downstream
of first part of the CDCA7L promoter sequence.
Finally, a third step was performed to replace the hph
coding sequence with the d2EGFP coding sequence.
To this end, a fragment corresponding to the d2EGFP
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sequence was amplified from the pCMV-d2EGFP-empty
plasmid (Addgene), by using the primers 5′-GGCGTCG
ACATGGTGAGCAAGGGCGAGGA-3′ and 5′-CGCGG
CCGCCACATTGATCCTAGCAGAAGC-3′, which carry
a 5′-overhang containing a SalI and a NotI restriction site,
respectively. This PCR product was introduced instead of
the hph sequence into the vector, now designated pC
DCA7L-prom/d2EGFP. All constructs were verified by
sequencing. For transfection of the pCDCA7L-prom/
d2EGFP plasmid, we used the Lipofectamine 2000 reagent
(Invitrogen) for MZ2-MEL3.1, BB74-MEL, and SK-MEL-
23 cell lines and the TurboFect reagent (Thermo Scien-
tific) for Mi665/2 cells, according to the manufacturer’s
instructions. Transfections were performed in 25 cm2
flasks containing cells at about 90 % confluency in a
medium without antibiotics. Cells were transfected with
10 μg of plasmid DNA, and the medium was replaced after
4 h of incubation. Two days after transfection, the cells
were transferred into medium containing 1 mg/mL (MZ2-
MEL3.1), 2 mg/mL (SK-MEL-23), 1.5 mg/mL (BB74-MEL),
or 0.8 mg/mL (Mi665/2) of geneticin (Gibco, Life Tech-
nologies) during a minimum of 7 days. RNA was extracted
between days 15 and 21 after transfection.
Quantitative RT-PCR
Total RNA samples were extracted using TriPure Isolation
Reagent (Roche Applied Science). Reverse transcription
was generally performed on 2 μg of total RNA using
oligo(dT) primers as described elsewhere [9]. Quantitative
RT-PCR amplifications were performed by using the
qPCR Core Kit (Eurogentec, Belgium). For qPCRs, either
SybrGreen or Taqman assays were performed (see
Additional file 10: Table S2). The primers and specific
5′-FAM/3′-TAMRA-labeled probes were synthesized com-
mercially (Eurogentec), and their sequences are available in
Additional file 10: Table S2. All qPCRs were performed in
duplicates. Expression levels were generally normalized as a
ratio to 10,000 ACTINB mRNA copies.
Bisulfite genomic sequencing and quantitative MS-PCR
To analyze the methylation levels of the MAGEA1 gene
and LINE-1 sequences, we resorted to quantitative
methylation-specific PCR (qMS-PCR). The reaction con-
ditions of the MAGEA1 and LINE-1 qMS-PCRs have
been described elsewhere [53, 54]. To evaluate the rela-
tive levels of MAGEA1 or LINE-1 demethylation in our
cell lines depleted or not in DNMT1, we calculated the
ratio of unmethylated/(methylated + unmethylated) in-
ferred from the -∂CTs in each sample. Methylation analyses
of the CDCA7L promoter were performed by bisulfite se-
quencing as follows. A first PCR was performed on 0.25 μg
of bisulfite-modified genomic DNA (50 s at 95 °C, 50 s
at 60 °C, and 90 s at 72 °C for 35 cycles) with the follow-
ing primers: 5′-TTTGYGAAGATAAGGTTAGTGGT-3′
(forward) and 5′-CCCACTACRCACACCTACAAA-3′
(reverse). Next, a second semi-nested PCR was performed
on a dilution 1:150 of the first PCR products with the
same amplification conditions. The forward primer was
the same than for the first PCR, and the reverse
primer was 5′-ACCRAACCCTCACCTAATAA-3′.
FACS analysis on propidium iodide labeled cells
After 7 days of doxycycline exposure, cells were released
by trypsin digestion, pelleted, and resuspended in 0.5 mL
of 1× PBS. Then, 1.5 mL of cold 70 % ethanol was added
dropwise to the cells, and the solution was stored at 4 °C.
Prior flow cytometric analysis, the cells were pelleted and
resuspended in 15 μL of 10 mg/ml RNAse. Two hundred
microliter of 50 μg/ml propidium iodide diluted in 1× PBS
was then added, and cells were incubated for 15 min at
room temperature. Ten thousand single cell events per
sample were analyzed for DNA content to identify
G0/G1 (2N DNA content), G2/M (4N DNA content), and
S-phase cells using a BD FACSVerse system (BD Biosci-
ences). The FlowJo 9.8.2 software was used to analyze the
data with the Watson Pragmatic model.
Western-blotting
For Western-blotting against the RB protein, whole cell
lysates were obtained by harvesting cells in RIPA lysis buf-
fer complemented with cOmplete Mini Protease inhibitor
cocktail (Roche) and PhosSTOP Phosphatase inhibitor
cocktail (Roche). For all other Western-blottings, nuclear
extracts were isolated via the NE-PER Nuclear and Cyto-
plasmic Extraction Reagents (Thermo Scientific) supple-
mented with cOmplete Mini Protease inhibitor cocktail
(Roche). Whole cell lysates or nuclear extracts were denatu-
rated for 10 min at 99 °C in the presence of Laemmli buffer
6× before loading and electrophoresis in a 8 % SDS-PAGE
gel. Proteins were thereafter submitted to an electrotransfer
on a polyvinylidene difluoride Immobilon®-P transfer mem-
brane (Millipore) during 1 h and 30 mins at 100 V at 4 °C.
The membrane was thereafter saturated in a PBS solution
containing 5 % non-fat milk and 0.05 % Tween 20 during
1 h at room temperature. Incubation with the primary
antibodies was performed in the same solution overnight at
4 °C for DNMT1, RB, or p80-Ku. Primary antibodies were
as follows: anti-DNMT1 rabbit polyclonal antibody (1:2000,
#ab19905, abcam), anti-Rb (C-15) rabbit polyclonal anti-
body (1:2000, #sc-50, Santa Cruz), and anti-p80-Ku mouse
monoclonal antibody (1:1000, #05-393, Millipore). Follow-
ing incubation with the primary antibody, the membrane
was washed three times in PBS-Tween 0.05 % and then
incubated at room temperature for 1 h in the presence of
either HRP-conjugated goat anti-rabbit IgG antibody
(1:10,000, #ADI-SAB-300, Enzo Life Sciences) or HRP-
conjugated goat anti-mouse IgG antibody (1:2000, #sc-
2005, Santa Cruz). Signals on the membrane were revealed
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using the SuperSignal® West Pico Chemiluminescent Sub-
strate (Pierce, Thermo Scientific) and after exposure to Fuji
Medical X-RAY films (Fujifilm). Before applying a new anti-
body, the membrane was subjected to a 10-min incubation
in 0.4 M NaOH at room temperature, three washes in
PBS-Tween 0.05 %, and incubation in a PBS solution con-
taining 5 % non-fat milk and 0.05 % Tween 20 during 1 h
at room temperature.
ChIP assays and antibodies
Chromatin immunoprecipitation (ChIP) was performed
on adherent cell lines at about 90 % confluency in a 150-
mm culture dish containing 25 mL of growth media.
ChIP assays were carried out by following the Upstate
EZ-ChIP Kit protocol (Millipore, catalog no. 17–371),
and chromatin was sheared with the Bioruptor Sonicator
(Diagenode, cat. no. UCD-200 TM). The chromatin was
immunoprecipitated using the following antibodies: anti-
acetyl-Histone H3 polyclonal antibody (Upstate, cat. no.
06–599), anti-dimethyl-Histone H3 (Lys 4) polyclonal
antibody (Active motif, cat. no. 39141), anti-dimethyl-
Histone H3 (Lys 9) monoclonal antibody (Diagenode,
cat. no. Mab-154-050), anti-trimethyl-Histone H3 (Lys
27) polyclonal antibody (Upstate, cat. no. 17–622), and
normal rabbit IgG (Santa Cruz Biotechnology, cat. no.
sc-2027). DNA purified from both the immunoprecipi-
tated and pre-immune (input) samples was subjected to
quantitative PCR amplification using the following
primers and probes: 5′-CAAAGTGAACCCTGTAGCA
A-3′(forward; −525), 5′-GCTGCAACCCCTGTCTCT-3′
(reverse; −389), 5′-6FAM-ACAAAACAAAACAAGCCC
CAAAGCC-TAMRA-3′ (probe; −460) for the CDCA7L
gene, and 5′-TACTAGCGGTTTTACGGGCG-3′ (for-
ward; −230), 5′-CGAACAGGAGGAGCAGAGAGCGA-3′
(reverse; +46), 5′-6FAM-AGGCCTCAAGACCTTGGGC
TGGGACTG-TAMRA-3′ (probe; −88) for the GAPDH
gene. The results (% of input) were represented as the ratio
of immunoprecipitated DNA/input DNA inferred from
the -∂CTs in each sample.
Additional files
Additional file 1: Figure S1. Activation profile of other CG genes in
the 45-MelCells dataset. Relative expression values (ratio to mean in all
samples) were obtained for all X-linked CG genes listed in Simpson
et al. (n = 41; ref. [11]), but excluding the 11 reference CG genes used
for determination of the CGAS. The threshold for activation was defined
as described in the materials and methods section. A majority of CG
genes (n = 26, shown in the upper part) shows preferential activation in
melanoma cell lines with a CGAS ≥7. (PDF 3940 kb)
Additional file 2: Table S1. List of 14 genes overexpressed in melanoma
cell lines with a CGAS ≥7 (max 10 % FDR). List of 192 PCCG genes. List of 64
ICCG genes. (PDF 52 kb)
Additional file 3: Figure S2. Overlap between ICCG genes and the set
of genes that were down-regulated upon DNMT1 depletion in the Sen
et al. study (ref. [28]). The Venn diagram shows exclusive overlap of the
Sen set of genes with ICCG genes, but not with PCCG genes. The 21
genes common to ICCG genes and the Sen set of genes are listed.
Reference ICCG genes, which were used in subsequent analyses are
highlited in bold. The other reference ICCG gene, CDCA7L, is lacking in
this list of common genes, because it was initially not represented on the
microarray used by Sen et al. (PDF 3940 kb)
Additional file 4: Figure S3. Exposure of HCT116 cells to DNMT1
inhibitor decitabine leads to down-regulation of cell mitosis/division-
associated genes, and these genes show significant overlap with the
group of ICCG genes. A) Genes showing transcriptonal up-regulation
(fold change ≥4, adjusted p value ≤0.01, n = 165) or down-regulation
(fold change ≤0.5, adjusted p value <0.01, n = 172) upon exposure to
the DNMT1 inhibitor (GSE30985 dataset) were analyzed for enrichment of
ontology terms. B) Overlap between down-regulated genes and ICCG
genes was analyzed, and is expressed as observed/expected match
ratio (log2). Fisher test was used for statiscal analysis: *p ≤ 0.05. C)
Changes of expression observed in cells treated with the DNMT1
inhibitor are given for the 11 reference CG genes, and for ICCG
genes (those that overlap with the down-regulated group of genes
in the Sen et al. study; see Additional file 3: Figure S2). (PDF 3940 kb)
Additional file 5: Figure S4. Even after adjustment for cell proliferation,
DNMT1 mRNA expression levels remain lower in CGAS-high melanoma
samples. As DNMT1 shows a peak of mRNA expression during the S-phase
of the cell cycle, reduced expression of this gene may reflect differences in
cell proliferation rates rather than transcriptional down-regulation. To
discriminate between these two possibilities, we resorted to a previously
described strategy, wherein DNMT1 expression levels were reported to that
of another gene (HIST2H4A) showing peak expression during the S-phase
(Lee et al. Proc Natl Acad Sci USA, 1996, 93:10366). A) Cell cycle-dependent
mRNA expression levels, as provided by Cyclebase, confirm peak expression
of DNMT1 and HIST2H4A during the S-phase. B) DNMT1/HIST2H4A
expression ratios were calculated (log2), and are represented in CGAS-
low and CGAS-high melanoma samples (red bar at median). Statistical
analysis was performed with the Mann–Whitney test. mRNA ratios
remained lower in CGAS-high melanoma samples, thereby excluding
differential proliferation rates as a cause of reduced DNMT1 mRNA
expression. (PDF 3940 kb)
Additional file 6: Figure S5. DNMT1 expression levels show no
correlation with histological staging or patient survival in cutaneous
melanoma. DNMT1 mRNA expression levels and clinical data were
obtained from the TCGA dataset of cutaneous melanoma. A) The graphs
represents relative DNMT1 mRNA expression (log2 scale) in melanoma
tissue samples grouped according to Clark stage (number of samples in
each group is indicated between parentheses). Statistical analysis with
Anova and Bonferroni’s multiple comparison tests revealed no significant
differences. B) Melanoma samples were separated into DNMT1-low
(<0.7 fold mean probe intensity level, n = 57) and DNMT1-high (>1,3
fold mean probe intensity level, n = 48), and a Kaplan-Meier plot was
obtained for the two corresponding groups of patients. Log rank test
revealed no significant difference in survival between the two groups.
(PDF 3940 kb)
Additional file 7: Figure S6. Illustration of selected pTctrl and
pTshDNMT1 clones derived from either HNEM-hTERT or BJ-hTERT cells.
Light and fluorescence microscopy images of selected clones, either
without (− doxy) or after (+ doxy) treatment with 1 μg/mL of doxycycline
during 3 days. Selected clones show ~100 % tTFP positive cells after
doxycycline exposure. (PDF 3940 kb)
Additional file 8: Figure S7. Evidence of cell cycle-associated expression
of representative ICCG and non-ICCG genes. A, Cyclebase data of cell cycle
mRNA expression peaktime for the 4 representative ICCG genes and the 3
non-ICCG genes (KIF5B, PWP1 and CEP70). B, Relative mRNA levels of the
genes were determined by RT-qPCR in BJ-hTERT fibroblasts cultured in
the absence of serum during 7 days (− FBS d7). Values derived from 3
independent experiments and are expressed relative to the levels
found in cells cultured in the presence of serum (+ FBS). **p <0.01,
***p <0.001, ****p <0.0001. (PDF 3940 kb)
Cannuyer et al. Clinical Epigenetics  (2015) 7:114 Page 15 of 17
Additional file 9: Figure S8. shRNA-dependent inhibition of RB1, but
not of p107 and p130, induces up-regulation of ICCG genes in human
fibroblasts. Microarray expression data were extracted from the GSE19864
dataset (Chicas et al., Cancer Cell, 2010, 17:376). Fold change in expression is
given for the 21 ICCG genes that overlapped with the Sen set of genes
(see Additional file 3: Figure S2), and corresponds to the ratio (log2) of
probe intensities between the indicated condition and control cells.
(PDF 3940 kb)
Additional file 10: Table S2. qPCR primers and probes. The sequences
of PCR primers and Taqman probes (if used) are provided. (PDF 48 kb)
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